Literature DB >> 16966530

NIPPV: a treatment for ALS whose time has come.

Terry D Heiman-Patterson, Robert G Miller.   

Abstract

Entities:  

Mesh:

Year:  2006        PMID: 16966530     DOI: 10.1212/01.wnl.0000238978.69141.57

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

Review 1.  Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials.

Authors:  Paul H Gordon
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

Review 2.  FTD and ALS: a tale of two diseases.

Authors:  R Ferrari; D Kapogiannis; E D Huey; P Momeni
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

3.  Determinants of accepting non-invasive ventilation treatment in motor neurone disease: a quantitative analysis at point of need.

Authors:  Rosanna Cousins; Hikari Ando; Everard Thornton; Biswajit Chakrabarti; Robert Angus; Carolyn Young
Journal:  Health Psychol Behav Med       Date:  2013-11-01

4.  Aspirin use associated with amyotrophic lateral sclerosis: a total population-based case-control study.

Authors:  Ching-Piao Tsai; Feng-Cheng Lin; Johnny Kuang-Wu Lee; Charles Tzu-Chi Lee
Journal:  J Epidemiol       Date:  2014-12-27       Impact factor: 3.211

5.  Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan.

Authors:  Charles Tzu-Chi Lee; Yi-Wen Chiu; Kai-Chen Wang; Chi-Shin Hwang; Kuan-Hsiang Lin; I-Ta Lee; Ching-Piao Tsai
Journal:  J Epidemiol       Date:  2012-10-27       Impact factor: 3.211

6.  Factors associated with assisted ventilation use in amyotrophic lateral sclerosis: a nationwide population-based study in Korea.

Authors:  Seo Yeon Yoon; Han-Kyoul Kim; Mi Ji Kim; Jee Hyun Suh; Ja-Ho Leigh
Journal:  Sci Rep       Date:  2021-10-04       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.